Malaria vaccine live unattenuated plus chloroquine - Sanaria

Drug Profile

Malaria vaccine live unattenuated plus chloroquine - Sanaria

Alternative Names: PfSPZ Challenge plus chloroquine; PfSPZ CVac; PfSPZ malaria vaccine live unattenuated plus chloroquine - Sanaria; Plasmodium falciparum sporozoite vaccine live unattenuated plus chloroquine - Sanaria

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator Sanaria
  • Developer National Institute of Allergy and Infectious Diseases; Sanaria
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Falciparum malaria

Most Recent Events

  • 01 Dec 2016 Phase-I clinical trials in Falciparum malaria (Prevention) in Mali (IV) (NCT02996695)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Falciparum-malaria(Prevention) in Netherlands (Intradermal, Injection)
  • 01 Apr 2016 Sanaria completes a phase I trial in Falciparum malaria (Prevention) in Germany (NCT02115516)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top